Extreme Bearish Acceleration
Braveheart Bio (BRVE) has sent shockwaves through the small-cap biotech sector after its short interest surged by a staggering 36.5 percentage points over the past seven days. With total short interest now exceeding 226% of its free float, the stock is exhibiting the classic characteristics of a highly distressed equity where borrow supply is likely non-existent.
Squeeze Potential
Such an extreme level of short interest—well above 100% of the float—is statistically rare for a company of this size. This indicates a deeply held, perhaps aggressive, bearish conviction that is now pushing against potential borrow limits. For retail traders, this is a clear sign that the stock is caught in a high-stakes battle between short sellers and those looking to trigger a forced-buyback event.
Key Takeaways
- Short interest increased by 36.5 percentage points in a week.
- Total short interest sits at an extreme 226% of float.
- Indicates extreme market dislocation and high squeeze risk.
The Bottom Line
Braveheart Bio is the epicenter of a massive short-selling battle. With SI at 226%, any positive catalyst could result in extreme, rapid price action due to forced covering.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.